Literature DB >> 14700504

Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients.

Michael H Alderman1, Hillel W Cohen, Jean E Sealey, John H Laragh.   

Abstract

BACKGROUND: The renin-angiotensin system (RAS) maintains hemodynamic integrity by modulating both volume and vasoconstriction through a cybernetic feedback control mechanism. In addition, angiotensin II, the active component of the RAS, can be vasculotoxic and, in hypertensive individuals, is associated with increased cardiovascular morbidity and mortality. The objective of this study was to determine the distribution and determinants of plasma renin activity (PRA) in a representative sample of hypertensive persons.
METHODS: We systematically measured PRA in 4170 untreated participants in a systematic work site-based, hypertension treatment program.
RESULTS: In this multiethnic employed population, patients were classified as follows: low renin, <0.65 ng/mL/h (30% of the sample); medium renin, 0.66 to 4.5 mg/mL/h (60%); or high renin, >4.5 ng/mL/h (10%). Low renin patients were more likely to be African American, female, and slightly older. However, the majority of women and African American individuals were not low renin. The 469 diabetic subjects distributed across renin categories, as did the group as a whole.
CONCLUSIONS: This systematic study of PRA in a large community sample of hypertensive patients reveals a wide distribution of activity level, with identifiable differences according to ethnicity, age, and sex but not diabetic status. However, these demographic differences were more quantitative than qualitative and do not provide a useful basis for estimation of the activity of the RAS. Instead, in hypertensive subjects, direct measurement of PRA is necessary, both for prognosis and for guiding hypertensive therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14700504     DOI: 10.1016/j.amjhyper.2003.08.015

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  22 in total

1.  Integrative Blood Pressure Response to Upright Tilt Post Renal Denervation.

Authors:  Erin J Howden; Cara East; Justin S Lawley; Abigail S L Stickford; Myrthe Verhees; Qi Fu; Benjamin D Levine
Journal:  Am J Hypertens       Date:  2017-06-01       Impact factor: 2.689

Review 2.  Hypertension Treatment in Blacks: Discussion of the U.S. Clinical Practice Guidelines.

Authors:  Stephen K Williams; Joseph Ravenell; Sara Seyedali; Sam Nayef; Gbenga Ogedegbe
Journal:  Prog Cardiovasc Dis       Date:  2016-09-29       Impact factor: 8.194

3.  The absence of intrarenal ACE protects against hypertension.

Authors:  Romer A Gonzalez-Villalobos; Tea Janjoulia; Nicholas K Fletcher; Jorge F Giani; Mien T X Nguyen; Anne D Riquier-Brison; Dale M Seth; Sebastien Fuchs; Dominique Eladari; Nicolas Picard; Sebastian Bachmann; Eric Delpire; Janos Peti-Peterdi; L Gabriel Navar; Kenneth E Bernstein; Alicia A McDonough
Journal:  J Clin Invest       Date:  2013-04-24       Impact factor: 14.808

Review 4.  Renin: friend or foe?

Authors:  Morris J Brown
Journal:  Heart       Date:  2007-05-08       Impact factor: 5.994

Review 5.  Aliskiren--mode of action and preclinical data.

Authors:  Dominik N Müller; Wolfgang Derer; Ralf Dechend
Journal:  J Mol Med (Berl)       Date:  2008-04-29       Impact factor: 4.599

Review 6.  Clinical pharmacokinetics and pharmacodynamics of aliskiren.

Authors:  Sujata Vaidyanathan; Venkateswar Jarugula; Hans Armin Dieterich; Dan Howard; William P Dole
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Renal angiotensin-converting enzyme is essential for the hypertension induced by nitric oxide synthesis inhibition.

Authors:  Jorge F Giani; Tea Janjulia; Nikhil Kamat; Dale M Seth; Wendell-Lamar B Blackwell; Kandarp H Shah; Xiao Z Shen; Sebastien Fuchs; Eric Delpire; Jorge E Toblli; Kenneth E Bernstein; Alicia A McDonough; Romer A Gonzalez-Villalobos
Journal:  J Am Soc Nephrol       Date:  2014-07-10       Impact factor: 10.121

8.  Nonmodulation as the mechanism for salt sensitivity of blood pressure in individuals with hypertension and type 2 diabetes mellitus.

Authors:  Patricia C Underwood; Bindu Chamarthi; Jonathan S Williams; Anand Vaidya; Rajesh Garg; Gail K Adler; Marissa P Grotzke; Gitana Staskus; Devendra Wadwekar; Paul N Hopkins; Claudio Ferri; Anthony McCall; Donald McClain; Gordon H Williams
Journal:  J Clin Endocrinol Metab       Date:  2012-08-03       Impact factor: 5.958

Review 9.  Renal angiotensin-converting enzyme and blood pressure control.

Authors:  Kenneth E Bernstein; Jorge F Giani; Xiao Z Shen; Romer A Gonzalez-Villalobos
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-03       Impact factor: 2.894

10.  Aldosterone Antagonists or Renin-Guided Therapy for Treatment-Resistant Hypertension: A Comparative Effectiveness Pilot Study in Primary Care.

Authors:  Brent M Egan; Marilyn A Laken; Susan E Sutherland; Suparna Qanungo; Douglas O Fleming; Anne G Cook; William H Hester; Kelly W Jones; Gerard C Jebaily; Gregory T Valainis; Charles F Way; Mary Beth Wright; Robert A Davis
Journal:  Am J Hypertens       Date:  2016-04-13       Impact factor: 2.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.